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Summary
Introduction: The treatment of total hip arthroplasty (THA) infections is long and costly. How-
ever, the number of studies in the literature analysing the real cost of THA revision in relation
to their etiology, including infection, is limited. The aim of this retrospective study was to
determine the cost of revision of infected THA and to compare these costs to those of primary
THA and revision of non-infected THA.
Materials and methods: We performed a retrospective cost analysis for the year 2006 using
an identical analytic accounting system in each hospital department (according to internal
criteria) based on allotment of direct costs and receipts for each department. From January
to December 2006, 424 primary THA, 57 non-infected THA revisions and 40 THA revisions due to
infection were performed. The different cost areas of the patient’s treatment were identiﬁed.
This included preoperative medical work-up, medicosurgical management during hospital stay,
a second stay in an orthopedic rehabilitation hospital (ORH) and post-hospitalisation antibiotic
therapy after revision due to infection, as well as home-based hospitalisation (HH) costs, if
this was the selected alternative option. We used the national health insurance fee schedule
found in the ‘‘Common classiﬁcation of medical procedures’’ and the ‘‘General nomenclature of
professional procedures’’ applicable in France since September 1, 2005. Hospital costs included
direct costs (hospital overhead costs) and indirect costs, (medical, surgical, technical settings
and net general service expenses). The calculation of HH costs and ORH costs were based on the
average daily charge of these departments. The cost of primary THA was used as the reference.
We then compared our surgical costs with those found for the corresponding comparable hospital
stay groups (Groupes homogènes de séjour).
Results: The average hospital stay (AHS) was 7.5± 1.8 days for primary THA, 8.9± 2.2 days for
non-infected revisions and 30.6± 14.9 days for revisions due to infection. The rate of transfer
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to a rehabilitation hospital (ORH) was 55% for primary THA, 77% in non infected revision cases
and 65% in revisions due to infection. Moreover, 30% of these infected THA were prescribed
HH. Non-infected THA revisions cost 1.4 times more than primary THA. THA revisions due to
infection cost 3.6 times more than primary THA.
Discussion: The economic impact of THA infections is considerable. The extra costs are mainly
due to an extended hospital stay and to longer rehabilitation consuming signiﬁcant substantial
human and material resources.
Conclusion: The cost of treating infected THA is high. Treatment strategies should therefore
be optimised to increase the success rate and minimise total costs.
Level of evidence: Level IV. Economic and decision analyses, retrospective study
© 2010 Elsevier Masson SAS. All rights reserved.
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•Introduction
According to the technical agency of information on
hospitalisation (Agence technique de l’information sur
l’hospitalisation) which centralises national data for the
program for the data processing of medical information,
117,400 primary total articular arthroplasties (THA) were
performed in 2007 in France and 22,427 hip arthroplasties
were revised. Despite improvement in procedures for antibi-
otic prophylaxy and the ﬁght against nosocomial infections,
the risk of infection persists and is generally estimated to
be less than 1% in primary THA [1].
Infected arthroplasties are a source of morbidity and
even mortality, if infection is acute (septicemia) in these
often elderly patients. The cost of treatment is high for
society due to the necessity of repeated interventions and
hospitalisations and long term intravenous or oral antibiotic
treatment.
The number of cost-analysis studies on primary THA is
limited [2,3]. According to one study by Bozic and Ries [4],
the cost of treatment of an infected hip replacement is
approximately 100,000 US dollars per patient, or an annual
cost of 100 million US dollars. This ﬁgure does not include the
economic costs of this disease due to sick leave, or possible
disability payments.
The aim of this study was to quantify the cost of
management of infected THA at the ‘‘Groupe hospitalier
Diaconesses-Croix Saint-Simon’’ Hospital and to compare it
to the cost of primary THA and the management of non-
septic THA.
Materials and methods
A retrospective cost analysis for the year 2006 was per-
formed in each department of our institution using an
analytic accounting system. From January to Decem-
ber 2006, 474 primary THA, 57 aseptic revisions and 40 septic
revisions were performed.
We identiﬁed the different cost areas by following the
patients through the clinical treatment process (Fig. 1).
After the surgical indication was decided, a standardised
preoperative evaluation was performed. The main differ-
ence between the preoperative evaluation of a primary THA
and of an aseptic THA revision was the aspiration arthrogra-
phy [5] of the hip with bacteriological culture analysis of the
•spirate culture or liquid from articular lavage. At least, one
one scintigraphy was performed during septic THA revision.
Different costs of medicosurgical treament included:
medical and non-medical human resource costs, mainly
salaries;
medical prescriptions (pharmaceutical products, medical
products, medical transportation) and hip prostheses;
general expenses, amortisement costs (medical material
and computers) and ﬁnancial expenses;
net costs of medicotechnical platforms: surgical unit,
anesthesia, physiotherapy, radiology, laboratory costs,
day hospital services, pharmacy;
net cost of general services: administrative, mainte-
nance, meal and linen services.
An hourly cost was determined for the surgical unit by
ividing the cost of orthopedics (aseptic and septic) and
nesthesia by the total number of hours that orthopedic
urgeons and anesthesiologists spent in the operating room
lus the number of hours spent in the surgical recovery room
SRR).
In case of revision of septic THA, intravenous antibi-
tic therapy was administered for 6weeks, then orally for
nother 6weeks.
The patient was discharged to go home or to an ORH
epending on his/her functional condition, degree of inde-
endence, and the type of rehabilitation required. For
eptic THA revisions, the patient was discharged either to
n ORH or received home hospital care (HH):
HH could be proposed before the end of intravenous
antibiotic treatment if the clinical and biological course
of the disease was favourable, if the patient’s functional
condition was satisfactory and if they had help at home
for daily activities (shopping, meals. . .). In this case, home
hospitalisation was monitored by a nurse with a weekly
biological work-up, (NFS, blood ion, liver tests, CRP) and
sent by fax to the patient’s physician. At the end of
intravenous antibiotic treatment, an average of 6weeks
of oral antibiotic treatment had begun. The patient
also underwent standard biological laboratory tests every
15 days;
patients were transferred to an ORH when their clin-
ical condition required additional medical care and/or
they required physiotherapy and rehabilitation. Orthope-
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We applied the rates found in the national health insurance
fee schedule of the common classiﬁcation of medical acts
and the general nomenclature of professional acts applica-
ble on September 1, 2005 (Table 1).igure 1 Clinic treatment process followed by patients for pr
dic rehabilitation and follow-up included several types of
rehabilitation:
◦ functional rehabilitation (involving corporal mobility),
◦ social rehabilitation (involving psychological matters),
◦ professional rehabilitation (involving reintegration into
the work force).
Maintaining independence or regaining independence in
dependent patients was one of the main goals of a stay in
an ORH.Table 1 Cost of preoperative evaluation in Euros.
Preoperative tests
Consultation surgeon
Consultation anesthesiologist
Standard blood count (NFS, ESR, CRP, blood ions, liver tests, PT, AC
HIV, HBV, HCV serologies
ECBU
Frontal pelvic X-ray
Coxofemoral X-ray (2—3ﬁlms)
Panoramic dental X-ray
Chest X-ray
Aspiration arthrography of the hip
Hip arthrography
Bacteriological culture of articular aspirate
Bacteriological culture of articular lavage
Transthoracic echocardiogram
Doppler ultrasound of the supraaortic trunks
Bone scintigraphy 1
Bone scintigraphy 2
Totaly total hip arthroplasty (THA), aseptic or septic revision.
esults
reoperative evaluationPrimary THA Aseptic revision Septic revision
23 23 23
23 23 23
T) 63.18 63.18 63.18
95.58 95.58 95.58
20.25 20.25 20.25
19.95 19.95 19.95
33.25 33.25 33.25
21.26 21.26 21.26
21.28 21.28 21.28
— 19.16 19.16
— 69.16 69.16
— 74.25 74.25
— 33.75 33.75
— 95.16 95.16
— — 75.60
— — 193.19
— — 193.19
320.75D 611.44D 880.93D
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Table 2 Cost of surgery (MSO)a in Euros for a primary total hip arthroplasty.
Expenses Total 2006 in Euros Cost driver (CD) CD (Days
hours stays)
Cost of CD
in euros
Number of
cost drivers
Cost per
patient in Euros
Human resource costs 2,173,618b Number of days 8741 248.67 7.5± 1.8 d 1864.70± 457.40
Medical prescriptions besides
prostheses
144,046 Number of days 8741 16.48 7.5± 1.8 d 123.60± 30.30
Prosthesis Average cost of a prosthesis 2046.81 1 prosthesis 1808
General expenses,
amortisement and ﬁnancial
expenses
22,752 Number of days 8741 2.60 7.5± 1.8 d 19.50± 5
Surgical unit + anesthesia 3,046,936 Number of hours 5764 528.61 04 h 02± 01 h 02 (4.04± 1.04) 2134± 551
Physiotherapy 240,586 Number of days 8741 27.52 7.5± 1.8 d 206.40± 50.60
Radiology, laboratory tests,
day hospital
548,675 Number of stays 1357 404.33 1 404
Pharmacy 241,905 Number of days 8741 27.67 7.5± 1.8 d 207.50± 50.90
General expenses 836,591 Number of days 8741 95.71 7.5± 1.8 d 717.70± 176
Total per patient 7487.50± 1028D
Example: First line: the cost of all personnel in the orthopedic surgery unit itself in 2006 was 2,173,618 Euros. The cost driver chosen was the number of days of hospitalisation or 8741 days
for all the patients in the unit. The cost per working unit (2,173,618/8741) was 248.67 Euros. The average hospital stay of a patient operated on for primary THA was 7.5± 1.8 days. The
human resource costs for a patient who stayed 7.5 days were therefore 1865 Euros (248.67× 7.5).
a MSO: short-term treatment (medicine, surgery, obstetrics and odontology).
b Non-medical staff: 1,474, 680 Euros; medical staff: 698,938 Euros.
128
S.
Klouche
et
al.
Table 3 Costs of surgery (MSO) in Euros for revision of aseptic total hip arthroplasty.
Expenses Total 2006 in Euros Cost driver (CD) CD (Days
hours stays)
Cost per CD
in Euros
Number of CD Cost per
patient in Euros
Human resource costs 2,173,618a Number of days 8741 248.67 8,9± 2,1 2210± 536
Medical prescriptions
besides prostheses
144,046 Number of days 8741 16.48 8.9± 2.1 146.40± 35.50
Prothesis Average cost of a prosthesis 2046.81 1 prothesis 2047
General expenses,
amortisement and
ﬁnancial expenses
22,752 Number of days 8741 2.60 8,9± 2,1 23.1± 5.6
Surgical unit + anesthesia 3,046,936 Number of hours 5764 528.61 05 h 49± 01 h 35 (5.83± 1.6) 3079.70± 845
Physiotherapy 240,586 Number of days 8741 27.52 8.9± 2.1 244.6± 59.30
Radiology, laboratory,
day hospital
548,675 Number of stays 1357 404.33 1 404
Pharmacy 241,905 Number of days 8741 27.67 8.9± 2.1 245.90± 59.60
General expenses 836,591 Number of days 8741 95.71 8.9± 2.1 850.50± 206.10
Total per patient 9239.30± 1209.70D
a Non-medical staff: 1,474,680 Euros; medical staff: 698,938 Euros.
Table 4 Cost of surgery (MSO) in Euros for revision of septic total hip arthroplasty.
Expenses Total 2006 in Euros Cost driver (C.D.) C.D. (Days
Hours Stays)
Cost per CD
in Euros
Number of CD Cost per
patient in Euros
Personnel costs 1,541,036a Number of days 5002 308.08 30.7± 15 j 9948± 4610
Medical prescriptions besides
prosthesis
447,292 Number of days 5002 89.42 30.7± 15 j 2742.20± 1338
Prothesis Average cost of prosthesis 1862.47 1 prothesis 1862
General expenses,
amortisement and ﬁnancial
expenses
6456 Number of days 5002 1.29 30.7± 15 j 39.50± 19.30
Surgical unit + anesthesia 3,046,936 Number of hours 5764 528.61 05 h 29± 01 h 18 (5.49± 1.3) 2900.70± 694.30
Intensive care unit 261,008 Number of days 298 875.86 2.1± 1.9
Physiotherapy 63,367 Number of days 5002 12.67 30.7± 15 j 388.50± 189.60
Radiology, laboratory tests 212,027 Number of stays 208 1019.36 1 1019
Pharmacy 241,905 Number of days 5002 23.03 30.7± 15 j 706.20± 344.60
General expenses 586,293 Number of days 5002 117.21 30.7± 15 j 3594.40± 1754.10
Total per patient 23,757.20± 8235D
a Non medical staff: 1,029,165 Euros, medical staff: 511,871 Euros.
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Table 5 Cost of oral antibiotic treatment after home hospitalisation (HH).
Antibiotics Dosage Form Price per
box (euros)
Daily cost (euros) Cost of treatment
(42 days)
Clindamycinea 750—900mg× 3/d Gel 300mg
(box of 16)
8.63 4.04—4.85 170—204D
Rifampicineb 600—900mg× 2/d Gel 300mg
(box of 30)
17.53 2.34—3.50 98.28—147D
Peﬂoxacinec 400mg× 2 ou 3/d Cp 400mg
(box of 28)
86.91 6.20—9.31 260.4—391.02D
Ciproﬂoxacined 750—1000mg× 2/d Cp 500mg
(box of 12)
23.99 6—8 252—336D
Amoxicillinee 2—3 g× 3/d Cp 1 g
(box of 14)
5.29 2.26—3.40 95.23—142.83D
Ac.fusidiquef 500mg× 3/d Cp 250mg
(box of 10)
11.58 6.95 291.81D
Minocyclineg 100mg× 3/d Cp 100mg
(box of 15)
9.22 1.84 77.44D
Cefalexineh 1 g× 3/d Cp 1 g
(box of 6)
5.90 2.95 123.90D
a Dalacine® PFIZER, 23-25, avenue du Dr-Lannelongue, 75014 Paris.
b Rifadine® Sanoﬁ-Aventis France, 1-13, boulevard Romain-Rolland, 75014 Paris.
c Péﬂacine® Sanoﬁ-Aventis France, 1-13, boulevard Romain-Rolland, 75014 Paris.
d Ciﬂox® Bayer Santé, 13, rue Jean-Jaurès, 92807 Puteaux cedex.
e Clamoxyl® laboratoire GlaxoSmithKline, 100, route de Versailles, 78163 Marly-le-Roi cedex.
f ® s ce
ulogn
Paris
ations as well as the duration of anesthesia and monitoring
in the SRR were: 4 h 02± 1 h 02 (range 1 h 30—9h 50) for pri-Fucidine Leo Pharma, BP 311, 78054 Saint-Quentin-en-Yveline
g Mynocine® Tonipharm, 3, rue des Quatre-Cheminées, 92100 Bo
h Keforal® laboratoire Sciencex, 1, rue Edmond-Guillout, 75015
Medicosurgical costs during hospitalisation
The average hospital stay (AHS) was 7.5 days± 1.8
(range 3—25 days) for primary THA 8.9 days± 2.2
(range 5—19 days) for an aseptic revision and 30.6 days
± 14.9 (range 17—83 days) for a septic THA revision.
Figure 2 Duration of hospitalisation in orthopedic rehabilitation h
aseptic revision (with or without home hospitalisation [HH] or day h
m
r
rdex.
e-Billancourt.
.
To evaluate costs, the average duration of the three oper-ospital after primary total hip arthroplasty (THA) and septic or
ospital stays).
ary THA, 5 h 49± 1 h 35 (range 2 h 10—9h 10) for an aseptic
evision 5 h 29± 1 h 18 (range 3 h 30—8h 50) for septic THA
evision. The number of THA patients admitted to the inten-
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Table 6 Total costs in Euros excluding social expenses.
Primary THA Aseptic revision Septic revision
with HH
Septic revision with
hospitalisation in an
ORH
All septic
revisions
Preoperative evaluation 320.75 611.44 880.93 880.93
Hospitalisation (MSO) 7487.5± 1028 9239.3± 1209.7 23,757.2± 8235 23,757.2± 8235
HH 4953
Oral antibiotics 360.67
ORH 2800 4200 11,400
Total excluding social 9028± 1924D 12,409± 2059D 25,151± 7447D 36,687± 8107D 32,546± 9587D
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MSO: short-term treatment (medicine, surgery, obstetrics and od
hospital.
ive care unit could be broken down as follows: 12/474
2.5%) ‘‘primary THA’’ patients with an average stay in ICU of
.9± 1.8 (range 1—7days), 7/57 (12.3%) ‘‘aseptic revision’’
atients with an AHS of 1.6± 1 (range 1—3days) and 17/40
42.5%) ‘‘septic revision’’ patients with an AHS of 2.1± 1.9
range 1—7days). The surgical costs of primary THA, asep-
ic and septic THA revision are summarized in the following
ables (Tables 2—4).
ome hospitalisation
hirty percent of our patients who underwent revision of
eptic THA were prescribed HH. The average daily cost was
18.20D . The AHS for HH was 22.7 days. The total cost per
atient (average daily cost×AHS) was 4953D . This included
ll expenses.
ost of post-home hospitalisation oral antibiotic
reatment
he most frequently prescribed antibiotics are shown in
able 5. The average cost of oral antibiotic treatment was
etween 171.13 and 214.25D .
The cost of standard biological tests (NFS, ESR, CRP, blood
ons, liver tests, PT, ACT) was 63.18D . The cost of this
ollow-up was 189.54D . The average total cost of antibiotic
reatment was between 360.67 and 403.79D .
tay in a center for orthopedic rehabilitation and
ollow-up
he patients were admitted to different ORH’s. The rate of
ransfer to ORH’s was 55% for primary THA, 77% for revision
f aseptic THA and 65% for revision of septic THA.
T
s
m
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Table 7 Average cost in Euros of one-stage versus two-stage sep
Average cost MSO
One-stage 22,719± 8769D
Two-stage 38,628± 9800Dlogy); HH: home hospitalisation; ORH: orthopedic rehabilitation
The minimum stay in an ORH for primary THA was 10
ays, 15 days for an aseptic revision, and 30 days for a sep-
ic revision. These stays were longer if there was additional
reatment required in HH care, day hospital care or for com-
lex surgical operations (associated bone graft, two-stage
urgery for septic THA), medical complications (comorbidi-
ies) or social problems (dependent or patients in isolated
iving alone or in isolated areas) (Fig. 2).
The daily cost of an ORH for a primary THA and an aseptic
HA revision was 280D , while it was 380D for a septic THA.
he difference in the daily cost between the management
f aseptic and septic THA can be broken down in the fol-
owing manner: 8D for laboratory tests, 27D for antibiotics
nd 65D for healthcare personnel. The total minimum cost
f hospitalisation in an ORH (average daily cost×AHS) was
800D for primary THA, 4200D for revision of aseptic THA
nd 11,400D for a septic THA revision.
otal cost
able 6 shows the total costs excluding social expenses.
able 7 provides the ﬁgures for the subgroups that under-
ent one or two stage revision of THA.
Revision of aseptic THA cost 1.4 times more than primary
HA. Revision of septic THA cost 2.6 times more than aseptic
evisions and 3.6 times more than primary THA. Two-stage
eptic THA revisions cost 1.7 times more than a one-stage
evision (Table 7).
iscussiono our knowledge, this is the ﬁrst French cost analysis of
eptic THA revisions. This study helps show that the cost of
edicosurgical management in case of infection is consid-
rably higher than the fee allotted for the Related Hospital
tay Group (Groupe homogène de séjour) (GHS) used as
tic THA revision.
Average cost excluding social expenses
31,133± 9733D
54,098± 12,700D
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Table 8 Related hospital stay groups (Groupes homogènes de séjour) (GHSa) in 2006.
GHS GHMb GHM (related diagnostic group) title Fee 2006
Primary THA
2732 08C23V Hip prosthesis without associated complications or morbidity CMAc 5943D
2733 08C23W Hip prosthesis with associated complications or mobidity CMA 7176D
THA revision (aseptic or septic)
2731 08C22Z Interventions for revision of hip prosthesis 8123D
a GHS: related hospital stay group (groupe homogène de séjour): fee schedule for group homogène de malade (GHM) (related diagnostic
groups).
s): ba
ne, s
mor
n
T
s
2
M
t
G
f
s
tb GHM: related diagnostic groups (groupe homogène de malade
program for the data processing of medical information in medici
c CMA: associated complications and morbidity (complication et
a reference in the hospital accounting system. Indeed,
since the hospital reform law dated July 31, 1991, public
and private medical establishments are ﬁnanced accord-
ing to their activities based on data from the program for
the data processing of medical information (programme
de médicalisation des systèmes d’information). For short-
term treatment hospital stays — in medicine, surgery or
obstetrics (MSO)— this analysis is based upon the systematic
collection of a small amount of medical and administra-
tive data which makes up a standardised discharge summary
(résumé de sortie standardisé) (RSS). The data collected
is processed automatically and the RSS are classiﬁed into
a voluntarily limited number of groups with similar costs
and medical diagnoses: called related diagnostic groups
(Groupes homogènes de malades) (GHM). A related hospi-
tal stay group (GHS) is a fee schedule established for these
related diagnostic groups (GHM). The GHS for THA in 2006
are summarized in Table 8. Unfortunately, the system does
r
(
b
F
Table 9 Related Hospital Stay Group (Groupes Homogènes de Sé
GHS GHM GHM (related diagnostic group) title
Primary THA
2881 08C471 Hip arthroplasty for recent traumatism, level
2882 08C472 Hip arthroplasty for recent traumatism, level
2883 08C473 Hip arthroplasty for recent traumatism, level
2884 08C474 Hip arthroplasty for recent traumatism, level
2885 08C481 Other hip arthroplasties level 1
2886 08C482 Other hip arthroplasties level 2
2887 08C483 Other hip arthroplasties level 3
2888 08C484 Other hip arthroplasties level 4
Aseptic THA revision
2779 08C221 Interventions for hip arthroplasty revisions le
2780 08C222 Interventions for hip arthroplasty revisions le
2781 08C223 Interventions for hip arthroplasty revisions le
2782 08C224 Interventions for hip arthroplasty revisions le
Septic THA revisions in a center for osteoarticular infections
2922 08C561 Interventions for osteoarticular infections, le
2923 08C562 Interventions for osteoarticular infections, le
2924 08C563 Interventions for osteoarticular infections, le
2925 08C564 Interventions for osteoarticular infections, le
a The level of severity depends upon the associated diagnosis (comorsic category used for the medico-economic classiﬁcation in the
urgery, obstetrics and odontology.
bidité associée).
ot differentiate between revisions for septic and aseptic
HA, thus underestimating real costs. Indeed, MSO costs for
eptic THA revision were 2.9 times more than the allotted
006 GHS fees.
An update of the GHS fees has been available since
arch 1, 2009 (Table 9). However, the MSO cost of a sep-
ic revision is still 1.5 times more than the highest updated
HS fee.
The parameter which most signiﬁcantly affects this dif-
erence is the length of stay in MSO and ORH. This extended
tay is because of the patient’s general condition and the
ime necessary to adapt antibiotic treatment.
In 2006, the ORH stay was ﬁnanced by a global sum. A
eform is in progress to identify dominant morbidity groups
Groupes de morbidité dominante) (GMD).
Our results for primary THA are similar to those reported
y Caton [2]. However, to our knowledge, there are no
rench studies on septic revisions. Although it is not possi-
jour) (GHS) in 2009.
2009 Fee in Euros Length of stay (days)
Shortest stay Longest stay
1a 5623D 5 30
2 6177D 6 34
3 7007D 7 38
4 9427D 9 56
5505D 4 24
6259D 5 28
7247D 6 34
10,230D 9 53
vel 1 6963D 5 28
vel 2 8324D 7 37
vel 3 9761D 8 47
vel 4 14,062D 12 73
vel 1 4211D 3 18
vel 2 8670D 8 48
vel 3 11,197D 10 61
vel 4 15,081D 14 81
bidities).
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[32
le to compare our results directly to those of the American
tudy by Bozic et al. [3], the relative costs of revision of sep-
ic THA compared to an aseptic revision and a primary THA
n that study (2.8) (4.8) were comparable to our results.
The calculated cost corresponds to one hospital stay. If
evision includes two operations, the overall cost per patient
ncludes two hospital stays: ﬁrst for treatment of septic
HA and the second usually for aseptic THA which is why
two stage revision is more costly. A recent prospective
tudy [6,7] of 100 consecutive cases showed a cure rate
f 100% after at least 2 years of follow-up for one-stage
HA revisions, which was better than results found for two-
tage revisions. This difference is most probably due to the
ecisional tree used, which allowed selection of patients
ho could be treated with one operation. This suggests
hat treatment management strategies for septic THA should
e adapted to optimise costs while guaranteeing the best
esults in patients.
Our analytical study did not include ‘‘social’’ expenses
ssociated with sick leave, or any social aids which might
ave been received. Moreover, the other social conse-
uences of a debilitating disease requiring long and difﬁcult
reatment may be job loss or changing jobs due to the con-
equences of the handicap. These effects are difﬁcult to
uantify.
onclusionhe cost of managing a patient being treated for an infected
ip arthroplasty is 2.6 times greater than the cost of an asep-
ic revision and 3.6 times greater than primary THA. These
osts are higher than existing approved fee schedules (GHS).
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